Keyphrases
Advanced Colorectal Cancer
22%
Allogeneic
57%
Anti-PD-1 Therapy
22%
CCL27
22%
CD137
34%
Cellular Immune Response
35%
Change Analysis
22%
Clinical Trials
22%
Disease-free Survival
26%
DNA Vaccine
32%
Dose Level
30%
Effector T Cells
34%
Epigenetic Modulators
22%
Guadecitabine
45%
Immune Response
22%
Interleukin-15 (IL-15)
22%
Intravenous Ascorbate
22%
Ipilimumab
22%
Irinotecan
54%
Low-dose Cyclophosphamide
38%
Lymphoid Aggregates
32%
Macaque
26%
Memory Subsets
22%
Metastatic Colorectal Cancer (mCRC)
45%
Metastatic Pancreatic Ductal Adenocarcinoma
62%
Microsatellite Stable
22%
Multi-omics Analysis
22%
Neoadjuvant
74%
Neoadjuvant Therapy
36%
Nivolumab
45%
Overall Survival
65%
Pancreatic Adenocarcinoma
22%
Pancreatic Cancer
26%
Pancreatic Ductal Adenocarcinoma
75%
Pancreatic Tumor
22%
Pancreatic Tumor Cells
27%
Pembrolizumab
22%
Phase I Trial
45%
Phase II Study
45%
Plasmid
26%
Programmed Death-ligand 1 (PD-L1)
26%
Setpoint Following
22%
T Cells
34%
TAS-102
22%
Therapeutic Vaccine
53%
Trametinib
22%
Tumor Microenvironment
61%
Vaccine Response
33%
Viral Load
22%
Viral Replication
27%
Immunology and Microbiology
Adjuvant
6%
Adoptive Immunity
41%
Agonist
22%
Allele
18%
Antigen Specificity
16%
Arm
36%
CCL27
15%
CCL28
22%
CD4
7%
CD40 Ligand
13%
CD8
40%
Cutaneous T Cell Attracting Chemokine
22%
Cyclophosphamide
39%
Cytotoxic T-Cell
33%
Disease Free Survival
22%
DNA Vaccine
48%
Effector Cell
7%
Granulocyte
22%
Granulocyte Macrophage Colony-Stimulating Factor
10%
Human Immunodeficiency Virus
29%
Human Immunodeficiency Virus 1
21%
Human Immunodeficiency Virus Antigen
22%
Immune Response
54%
Immunotherapy
36%
Interleukin 12
22%
Interleukin 15
45%
Low Drug Dose
39%
Lymphocyte
13%
Macaca
26%
Macaca fascicularis
22%
Macrophage
22%
Major Histocompatibility Complex
13%
Monospecific Antibody
22%
Mouse
8%
Multi-Omics
22%
Neutrophil Granulocyte
11%
Nivolumab
42%
Overall Survival
50%
Plasmid
68%
Rhesus Monkey
45%
Simian Immunodeficiency Virus
59%
T Cell
49%
T-Helper Cell
33%
Tumor Cell Vaccine
22%
Urelumab
9%
Vaccination Policy
27%
Vaccine Adjuvant
25%
Vaccine Efficacy
100%
Viral Load
36%
Viral Replication
32%
Medicine and Dentistry
Adverse Event
5%
Anemia
5%
Anorexia
5%
Arm
48%
Azacitidine
5%
Cellular Infiltration
22%
Clinical Trial
10%
Colorectal Cancer
22%
Cyclophosphamide
36%
Cytotoxic T-Cell
11%
Disease Free Survival
12%
DNA Methyltransferase
11%
DNA Mismatch Repair
5%
Drive
5%
Effector Cell
10%
Granulocyte
22%
Granulocyte Macrophage Colony Stimulating Factor
7%
Histone Deacetylase
11%
Immune Cell Infiltration
5%
Immune Checkpoint Inhibitor
5%
Immunosuppressive Drug
5%
Immunotherapy
18%
Ipilimumab
22%
Low Drug Dose
36%
Lymphocytopenia
5%
Macrophage
36%
Maintenance Therapy
22%
Nausea
5%
Neoadjuvant Therapy
10%
Neoplasm
27%
Overall Survival
42%
Pancreas Adenocarcinoma
61%
Pancreas Cancer
45%
Pancreas Tumor
45%
Pancreatic Ductal Adenocarcinoma
27%
Pembrolizumab
22%
Programmed Death-Ligand 1
5%
Progression Free Survival
5%
Radiation Therapy
5%
Radioimmunotherapy
22%
Stereotactic Body Radiation Therapy
22%
Surgery
6%
T Cell
22%
Thrombocytopenia
8%
Tumor Cell
25%
Tumor Cell Vaccine
22%
Tumor Microenvironment
28%
Tumor Vaccine
22%
Vaccine Adjuvant
22%
Whole Body Radiation
17%
